DE69819016D1 - Arginine silicate inositol komplex und dessen verwendung - Google Patents

Arginine silicate inositol komplex und dessen verwendung

Info

Publication number
DE69819016D1
DE69819016D1 DE69819016T DE69819016T DE69819016D1 DE 69819016 D1 DE69819016 D1 DE 69819016D1 DE 69819016 T DE69819016 T DE 69819016T DE 69819016 T DE69819016 T DE 69819016T DE 69819016 D1 DE69819016 D1 DE 69819016D1
Authority
DE
Germany
Prior art keywords
pct
arginine silicate
inositol complex
silicate inositol
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69819016T
Other languages
English (en)
Other versions
DE69819016T2 (de
Inventor
Mark Mccarty
Jan Zielinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutrition 21 LLC
Original Assignee
Nutrition 21 LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrition 21 LLC filed Critical Nutrition 21 LLC
Publication of DE69819016D1 publication Critical patent/DE69819016D1/de
Application granted granted Critical
Publication of DE69819016T2 publication Critical patent/DE69819016T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/695Silicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/04Esters of silicic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69819016T 1997-02-12 1998-02-11 Arginine silicate inositol komplex und dessen verwendung Expired - Fee Related DE69819016T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US799784 1997-02-12
US08/799,784 US5707970A (en) 1997-02-12 1997-02-12 Arginine silicate complex and use thereof
PCT/US1998/002443 WO1998034647A1 (en) 1997-02-12 1998-02-11 Arginine silicate inositol complex and use thereof

Publications (2)

Publication Number Publication Date
DE69819016D1 true DE69819016D1 (de) 2003-11-20
DE69819016T2 DE69819016T2 (de) 2004-04-29

Family

ID=25176739

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69819016T Expired - Fee Related DE69819016T2 (de) 1997-02-12 1998-02-11 Arginine silicate inositol komplex und dessen verwendung

Country Status (16)

Country Link
US (3) US5707970A (de)
EP (1) EP1007096B1 (de)
JP (1) JP2001512443A (de)
KR (1) KR20000070977A (de)
CN (1) CN1182873C (de)
AT (1) ATE251914T1 (de)
AU (1) AU722975B2 (de)
BR (1) BR9807675A (de)
CA (1) CA2279233A1 (de)
DE (1) DE69819016T2 (de)
DK (1) DK1007096T3 (de)
ES (1) ES2209112T3 (de)
HU (1) HUP0001998A3 (de)
IL (1) IL130925A0 (de)
PT (1) PT1007096E (de)
WO (1) WO1998034647A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707970A (en) 1997-02-12 1998-01-13 Nutrition 21 Arginine silicate complex and use thereof
US20020068365A1 (en) * 1998-07-28 2002-06-06 Eric H. Kuhrts Controlled release nitric oxide producing agents
AU2001281337A1 (en) * 2000-07-24 2002-02-05 Nutrition 21, Inc. Arginine saccharate and use thereof
US6552074B2 (en) * 2000-11-16 2003-04-22 Fukumi Morishige Arginine/ascorbic acid mixed powder as an oral supplement
TWI283427B (en) * 2001-07-12 2007-07-01 Semiconductor Energy Lab Display device using electron source elements and method of driving same
WO2003053288A1 (en) * 2001-12-20 2003-07-03 Trivascular, Inc. Advanced endovascular graft
US7147661B2 (en) 2001-12-20 2006-12-12 Boston Scientific Santa Rosa Corp. Radially expandable stent
EP1534302A4 (de) * 2002-08-22 2009-01-07 Nutrition 21 Inc Argininsilikat/inositol-komplex und seine verwendung
US6803456B1 (en) * 2003-08-13 2004-10-12 Rutherford Chemicals Llc Process for the production of arginine-silicate complex
US7803178B2 (en) * 2004-01-30 2010-09-28 Trivascular, Inc. Inflatable porous implants and methods for drug delivery
JP4852033B2 (ja) * 2004-03-11 2012-01-11 トリバスキュラー インコーポレイテッド モジュール式血管内移植片
US7919620B2 (en) * 2005-06-01 2011-04-05 Coral Biotech Kabushiki Kaisha Agent for suppressing blood pressure elevation
ITMI20060677A1 (it) * 2006-04-06 2007-10-07 Damor Farmaceutici Profarmaci dell'arginina ad elevata attivita'terapeutica
EP2070541A4 (de) * 2006-09-21 2011-04-13 Toshiki Oguro Mittel zur förderung der regeneration von hartem gewebe
EP3050568B1 (de) 2007-03-13 2020-12-02 JDS Therapeutics, LLC Verfahren und zusammensetzungen zur verzögerten freisetzung von chrom
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
GB0805279D0 (en) * 2008-03-20 2008-04-30 Univ Nottingham Trent Food supplement
WO2012035364A1 (en) 2010-09-15 2012-03-22 Creogen D.O.O. Stabilized solution of ortho-silicic acid, its preparation and use
US8933022B2 (en) 2011-03-01 2015-01-13 Jds Therapeutics, Llc Methods and compositions for the treatment and prevention Hypoglycemia and related disorders
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
AU2016287489A1 (en) * 2015-06-30 2018-01-18 Nutrition 21, Llc Arginine silicate inositol for improving cognitive function
US10703608B2 (en) 2015-07-13 2020-07-07 Otis Elevator Company Deterrent device inhibition key
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
MX2018009748A (es) 2016-02-11 2019-02-07 Nutrition 21 Llc Composiciones que contienen cromo para mejorar la salud y el estado físico.
AU2017318672B2 (en) 2016-09-01 2022-03-10 Nutrition 21, Llc Magnesium biotinate compositions and methods of use
CA3118583C (en) 2018-11-02 2024-05-14 Nutrition 21, Llc Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers
AU2020407071A1 (en) 2019-12-16 2022-07-07 Nutrition 21, Llc Methods of production of arginine-silicate complexes
CA3237984A1 (en) * 2021-11-12 2023-05-19 Nutrition21, LLC Compositions and methods for treating or preventing myopathy in poultry

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3337403A (en) * 1963-09-05 1967-08-22 Hoffmann La Roche Stable and palatable pharmaceutical compositions
US4297349A (en) * 1980-04-15 1981-10-27 Sandoz, Inc. Silicon-bearing carboxylic acids and amides
US4385052A (en) * 1981-07-20 1983-05-24 International Plant Research Institute, Inc. Use of trialkylsilyl-6-aminonicotinamides for the treatment of psoriasis
FR2610522B1 (fr) * 1987-02-06 1989-08-18 Gueyne Jean Produit therapeutique a base de derives organiques du silicium
US5250569A (en) * 1991-04-22 1993-10-05 Godfrey Science & Design, Inc. Amino acid flavorings of aluminum astringent for oral use
US5622980A (en) * 1993-08-17 1997-04-22 Applied Analytical Industries, Inc. Oral compositions of H2-antagonists
FR2745498A1 (fr) * 1996-02-29 1997-09-05 Giroux Jean Marc Composition pur augmenter conjointement la tolerance biologique et l'efficacite amincissante des produits hyperproteines hypocaloriques destines au traitement de l'obesite
US5707970A (en) * 1997-02-12 1998-01-13 Nutrition 21 Arginine silicate complex and use thereof

Also Published As

Publication number Publication date
US6344444B1 (en) 2002-02-05
CA2279233A1 (en) 1998-08-13
BR9807675A (pt) 2000-02-15
CN1246801A (zh) 2000-03-08
ES2209112T3 (es) 2004-06-16
CN1182873C (zh) 2005-01-05
DK1007096T3 (da) 2003-12-01
WO1998034647A1 (en) 1998-08-13
HUP0001998A3 (en) 2002-01-28
JP2001512443A (ja) 2001-08-21
EP1007096A1 (de) 2000-06-14
AU6273798A (en) 1998-08-26
ATE251914T1 (de) 2003-11-15
KR20000070977A (ko) 2000-11-25
US5707970A (en) 1998-01-13
PT1007096E (pt) 2004-03-31
IL130925A0 (en) 2001-01-28
HUP0001998A2 (hu) 2000-10-28
AU722975B2 (en) 2000-08-17
DE69819016T2 (de) 2004-04-29
US6156735A (en) 2000-12-05
EP1007096B1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
DE69819016D1 (de) Arginine silicate inositol komplex und dessen verwendung
FI972164A0 (fi) Aerogeelipitoinen komposiittimateriaali, menetelmä sen valmistamiseksi ja sen käyttö
HUP0004592A2 (hu) VCAM-1 expresszió gátlására alkalmas vegyületek és eljárások
BG103793A (en) COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
HK1023987A1 (en) Sulphinic acid derivatives, method for producing, and their use
PT1303632E (pt) Oligossacarideos de galactomanano e processo para a sua preparacao bem como sua utilizacao
ATE234282T1 (de) Polymorphe verbindungen
ES2169362T3 (es) Glicoconjugados de derivados modificados de la camptotecina (union al ciclo a o b).
MY115211A (en) Novel amino acid derivatives, their preparation and use
HK1018701A1 (en) Benzopyran derivatives having leukotriene-antagonistic action.
PL340561A1 (en) Application of a combination of a converting enzyme inhibitor and a diuretic in treating microcirculatory disorders
ATE303362T1 (de) Chalcon-derivate mit antiproliferativer aktivität
NO972426L (no) Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose
BG105275A (en) Tan-1057 derivatives
BG102814A (en) New derivatives of carboxylic acid, their preparation and application
DE69535267D1 (de) Verwendung zur verabreichung von östrogen
ES2163001T3 (es) Nuevos derivados de borneol, procedimiento para su preparacion y su utilizacion farmaceutica.
BG104958A (en) Stable compositions comprising levosimendan and alginic acid
DE69531627D1 (de) Humane hypertrophe chrondrozyten zelllinien
PT751774E (pt) Derivados de dissulfureto de mercaptoacetilamida hipocolesterolemicos
ATE221068T1 (de) Anellierte beta-carboline
ATE198315T1 (de) Dimethyl-substituierte cyclohexandienderivate
UA30393A (uk) Спосіб лікування коронарного атеросклерозу

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee